Abstract：
Introduction: Robotic surgery using da Vinci surgical system has gained prominence in urology; emerging robotic platforms are expanding its applications and increasing affordability. We assess the feasibility and safety of a novel system, the Toumai® robotic system in various urological surgeries. Methods: This prospective study was conducted at the first affiliated hospital of Zhengzhou university. Twenty consecutive patients underwent renal and prostatic surgery with the Toumai. The study assessed technical feasibility (conversion rate) and safety (perioperative complications) of the procedures as primary outcomes. Secondary endpoints included key surgical perioperative outcomes: functional and oncologic results. The Endoscopic Surgical System operates within a master-slave protocol, comprising a Surgeon Console, Patient Platform, and Vision Platform. Results: Seventeen patients underwent various nephrectomy procedures and three underwent radical prostatectomy (RP). There was no conversion to alternative surgical approach; a single (Clavien-Dindo grade ≥3b) complication occurred, and no readmission was recorded within 30 days. The median operative time was 120, 140, and 210 minutes for partial nephrectomy (PN), radical nephrectomy, and RP, respectively. Off-clamp PN was performed in one case, and the warm ischemia time in the remaining two case was 18 minutes. The median docking time was 22 minutes for nephrectomy and 20 minutes for RP; no major robotic malfunction was encountered. At 3-month follow-up, no tumor recurrence was recorded, renal function was well preserved, and the continence status was satisfactory. Conclusions: We present the initial clinical utilization of an innovative robotic platform. Complex urological surgeries were successfully completed without conversions and with minimal complications. Further investigations are warranted to confirm these initial findings.
摘要：
简介：使用达芬奇手术系统的机器人手术在泌尿外科领域越来越突出；新兴的机器人平台正在扩大其应用范围并提高其可负担性。我们评估新系统的可行性和安全性，各种泌尿外科手术中的Toumai®机器人系统。方法:本前瞻性研究在郑州大学第一附属医院进行。连续20例患者接受了Toumai的肾脏和前列腺手术。该研究评估了手术的技术可行性（转换率）和安全性（围手术期并发症）作为主要结果。次要终点包括关键的围手术期结果：功能和肿瘤学结果。内窥镜手术系统在主从协议内运行，包括一个外科医生控制台，患者平台,视觉平台。结果：17例患者接受了各种肾切除术，3例接受了根治性前列腺切除术（RP）。没有转换为替代手术方法；发生单一（Clavien-Dindo等级≥3b）并发症，30天内没有再入院记录。肾部分切除术（PN）的中位手术时间为120、140和210分钟，根治性肾切除术,RP,分别。在一种情况下进行了非钳位PN，其余两例热缺血时间为18分钟。肾切除术的中位对接时间为22分钟，RP的中位对接时间为20分钟；没有遇到重大的机器人故障。在3个月的随访中，无肿瘤复发记录,肾功能保存完好,尿失禁状况令人满意。结论：我们介绍了创新机器人平台的初始临床应用。复杂的泌尿外科手术成功完成，没有转换，并发症最少。需要进一步调查以证实这些初步发现。
